Don't want emails from us anymore? Click here to unsubscribe.
Hello!
This is a brief update of our new alert today, NNVC.
Following our alert this morning, NNVC opened at 1.25 and throughout the day so far rallied to a high of 1.32, gains of +5%.
A breakout and close above its 50 day moving average of 1.27 could present increased gains.
In addition, NNVC has a RSI of 51, suggesting the potential for increased upside.
A few weeks ago, NNVC rallied as high as 1.55, more than 24% from today's open.
NNVC has a 200 day moving average of 1.62, 29% from today's open.
A few weeks ago the company announced:
"Measles Outbreak: NV-387 Promises To Be An Effective Drug To Treat Patients; We are Ready To Work With HHS, Says NanoViricides President Dr. Anil Diwan"
In this press release, the company stated:
"NanoViricides believes that NV-387, the Company's flagship broad-spectrum antiviral, would be a potentially effective treatment for measles, and is worth evaluating during the current emergency situation created by the spreading outbreak. This belief has a strong rationale as explained below."
Importantly:
"NV-387 is a broad-spectrum antiviral drug that has been found to be effective against many distinctly different virus families that use heparan sulfate proteoglycans (HSPG) during attachment to infect cells, including RSV, Influenza, COVID/Coronaviruses and Mpox/Smallpox[2]."
Furthermore:
"The fact that even vaccinated children are being hospitalized with the current measles virus should not be taken lightly, even though their percentage remains relatively small[5]. The vaccine strain of measles virus is derived from genotype A, whereas the current infection in Texas is driven by genotype D.8. The standard measles live attenuated virus vaccine since circa 1968 has continued to remain highly effective because the measles virus has undergone very few mutations over centuries, and because this virus only infects humans and does not have any other animal reservoirs to sustain it. However, this situation appears to be changing. Over the last decade, several genotypes arose and only a few have survived in the last few years, indicating a gain in fitness, as well as divergence from the original genotype A, which is still the only vaccine strain. It is not unlikely that the historically known 95-97% effectiveness of the standard measles vaccine may have begun to wane as new virus variants arise under the selective pressure of the current vaccine."
Sadly, as the company notes, "Not having a drug to treat measles has resulted in a critical gap in the outbreak response".
In addition, as the company states, "As discussed in prior press releases, NV-387 is expected to remain an effective treatment even as viruses mutate."
We are continuing to monitor this opportunity.
Sources: PR1, PR2, PR3, PR4, PR5, Website, Chart
Happy Trading!
AwesomeStocks
Note: We encourage all traders and investors to develop personal trading rules that you can follow and that work for you. Always protect your downside and note that we alert extremely volatile short-term opportunities. Before investing in securities, you should always consult with your financial, tax and legal advisor and never invest money you cannot afford to lose.
Tidak ada komentar:
Posting Komentar